Johnson & Johnson $JNJ Shares Sold by Builder Investment Group Inc. ADV

Builder Investment Group Inc. ADV trimmed its position in Johnson & Johnson (NYSE:JNJ) by 0.4% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 29,836 shares of the company’s stock after selling 133 shares during the period. Johnson & Johnson accounts for about 1.1% of Builder Investment Group Inc. ADV’s portfolio, making the stock its 21st largest position. Builder Investment Group Inc. ADV’s holdings in Johnson & Johnson were worth $4,557,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Highline Wealth Partners LLC lifted its holdings in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $47,000. 1248 Management LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $179.69 on Monday. The company’s fifty day moving average price is $174.41 and its 200 day moving average price is $162.05. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market capitalization of $432.75 billion, a P/E ratio of 19.22, a P/E/G ratio of 2.29 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the business earned $2.82 EPS. Johnson & Johnson’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Analysts Set New Price Targets

A number of research firms have issued reports on JNJ. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. UBS Group increased their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a report on Thursday, July 17th. Citigroup increased their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, August 21st. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $181.40.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.